Amneal Completes Hat Trick With Delayed $2.6bn US Pegfilgrastim Entry
Developed With Kashiv BioSciences, Fylnetra Is Sixth Biosimilar On The Market
With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.
You may also be interested in...
Coherus Delivers With Pegfilgrastim Autoinjector Launch
Amid increasing competition on biosimilar pegfilgrastim in the US, Coherus is looking to bolster its position with the launch of an Udenyca autoinjector presentation, while it awaits approval for a rival to Amgen’s Neulasta Onpro on-body injector device later this year.
‘First Of Many’ For Kabi As It Rolls Out Its First Biosimilar – Pegfilgrastim
Fresenius Kabi has delivered on long held ambitions to join the biosimilars party in the US, offering another pegfilgrastim subcutaneous injectable in a crowded market of biosimilar sponsors.
Amneal Makes It Three With Pegfilgrastim Approval
Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.